Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)

整个生命周期精神分裂症的优化和个性化干预措施 (OPAL)

基本信息

批准号：
10623751
负责人：
THOMAS SCOTT STROUP
金额：
$ 209.08万
依托单位：
NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-04-01 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10623751
关键词：
Acceleration Address Adolescence Advocate Affect Area Assertiveness Assessment tool Attention Black, Indigenous, People of Color Caring Cessation of life Clinic Clinical Clinical Research Cognition Cognitive Communication Communities Data Dementia Development Diagnosis Disease Effectiveness Ensure Europe Formulation Fostering Goals Health Health Technology Homelessness Impairment Individual Inequity Infrastructure Intervention Interview Longevity Measurement Mental Health Methodology Methods Mobile Health Application Names New York Occupational Outcome Participant Persons Pharmaceutical Preparations Pilot Projects Policy Maker Premature Mortality Process Qualitative Methods Recommendation Regimen Research Personnel Research Support Resource Allocation Resources Risk Safety Schizophrenia Scientist Services Strategic Planning Target Populations Testing Training Translational Research Treatment Effectiveness United States Centers for Medicare and Medicaid Services Work clinical translation compare effectiveness dementia risk disability disability risk effective intervention emerging adult end of life ethnoracial evidence base experience feasibility testing first episode psychosis flexibility health disparity improved individualized medicine innovation interdisciplinary collaboration mHealth mood symptom novel people of color persistent symptom person centered personalized intervention personalized medicine practice setting premature psychotic symptoms reduce symptoms routine practice satisfaction service delivery shared decision making side effect skills social social health determinants tool training opportunity treatment optimization treatment strategy

项目摘要

The OPAL Center is named after its goal of Optimizing and Personalizing interventions for people with schizophrenia Across the Lifespan. The target population for this ALACRITY Center is people diagnosed with schizophrenia, which typically affects individuals from adolescence or early adulthood until the end of life. Affected individuals commonly have impaired social and occupational functioning; experience persistent psychotic and mood symptoms; have cognitive problems that may progress; and are at risk for disability and premature death. Black, Indigenous, and People of Color (BIPOC) individuals are particularly at risk of poor outcomes. The goal of this renewal application is to extend our efforts to accelerate the development and implementation of effective, individualized treatments for schizophrenia in real clinical settings. The specific aims of the Center renewal application are as follows: 1. Strengthen our infrastructure that supports research that examines innovative ways to optimize treatments for people with schizophrenia throughout the lifespan and that accelerates the translation of clinical research on schizophrenia to routine practice settings. 2. Conduct projects that develop, adapt, and test innovative, accessible, and person-centered interventions that improve engagement in treatment and can be readily deployed. 3. Train scientists who will conduct translational research on interventions for schizophrenia. The OPAL Signature Project will use 16 years of data (2007-2022) from the Center for Medicaid and Medicare Services (CMS) to test hypotheses about risk factors for dementia among people diagnosed with schizophrenia and compare the effectiveness of treatment strategies after diagnosis of dementia. We will then integrate our findings to adapt a Cognitive Health Toolkit that provides assessment and management tools. Exploratory Project 1 tests a novel, person-centered approach to assessment and treatment initiation for BIPOC individuals with psychotic symptoms in community mental health clinics that incorporates an adapted version of the Cultural Formulation Interview to improve diagnosis and treatment engagement. Exploratory Project 2 will build on work done in Europe to adapt and test the feasibility and preliminary effectiveness of Flexible Assertive Community Treatment (ACT), which will allow ACT teams to allocate resources according to the individual needs of participants, improving efficiency and outcomes. Exploratory Project 3 uses mobile health (mHealth) technology to deliver measurement-based care and improve the person-centered outcomes of individuals with schizophrenia across the lifespan. OPAL projects use the Center's common resources and methodologies to improve implementation and personalization of treatments for important problems. Stakeholders help us to refine and adapt interventions for effective implementation in real-world settings.

OPAL 中心以其为患有以下疾病的人优化和个性化干预措施的目标而命名精神分裂症贯穿整个生命周期。该 ALACRITY 中心的目标人群是被诊断患有以下疾病的人精神分裂症，通常影响从青春期或成年早期直至生命终结的个体。受影响的个人通常有社会和职业功能受损；经验持久精神病和情绪症状；存在可能进展的认知问题；并面临残疾风险过早死亡。黑人、原住民和有色人种 (BIPOC) 个体尤其面临贫困风险结果。此续订申请的目标是扩大我们的努力，加速开发和在真实的临床环境中对精神分裂症实施有效的个体化治疗。中心续展申请的具体目的如下： 1. 加强我们的基础设施，支持研究优化创新方法对精神分裂症患者进行终生治疗，并加速临床转化将精神分裂症研究纳入常规实践环境。 2. 开展开发、调整和测试创新、可行且以人为本的干预措施的项目提高治疗参与度并且易于部署。 3. 培训科学家进行精神分裂症干预措施的转化研究。 OPAL 签名项目将使用医疗补助中心 16 年（2007 年至 2022 年）的数据和医疗保险服务 (CMS) 将在被诊断患有痴呆症的人群中测试有关痴呆症危险因素的假设精神分裂症并比较痴呆症诊断后治疗策略的有效性。我们随后将整合我们的研究结果以适应提供评估和管理工具的认知健康工具包。探索性项目 1 测试了一种新颖的、以人为本的评估和治疗启动方法为社区心理健康诊所中患有精神病症状的 BIPOC 个人提供服务，其中包括文化配方访谈的改编版本，以提高诊断和治疗的参与度。探索性项目 2 将建立在欧洲所做的工作的基础上，以适应和测试可行性和灵活自信社区治疗 (ACT) 的初步效果，这将使 ACT 团队能够根据参与者的个人需求分配资源，提高效率和成果。探索性项目 3 使用移动医疗 (mHealth) 技术提供基于测量的护理并改善精神分裂症患者一生中以人为本的结果。 OPAL 项目使用中心的共同资源和方法来改进实施和对重要问题进行个性化治疗。利益相关者帮助我们完善和调整干预措施在现实环境中有效实施。

项目成果

期刊论文数量（21）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Hearing Loss in Older People With Schizophrenia: Audiologic Characteristics and Association With Psychosocial Functioning.

老年精神分裂症患者的听力损失：听力特征及其与心理社会功能的关联。

DOI：
发表时间：
2024-04
期刊：
影响因子：
0
作者：
Saperstein, Alice M;Subhan, Bibi A;Golub, Justin S;Medalia, Alice
通讯作者：
Medalia, Alice

Unmet Opportunity: Intensive Care Transition Intervention for Individuals With Serious Medical-Psychiatric Illnesses.

未满足的机会：对患有严重医学精神疾病的个人进行重症监护过渡干预。

DOI：
发表时间：
2021
期刊：
影响因子：
0
作者：
Smith, Thomas E;Marino, Leslie A;Olfson, Mark
通讯作者：
Olfson, Mark

Means of suicide among adults with schizophrenia across the life span.

成年精神分裂症患者一生中的自杀方式。

DOI：
发表时间：
2023-01
期刊：
影响因子：
4.5
作者：
Bareis, Natalie;Olfson, Mark;Gerhard, Tobias;Rolin, Stephanie;Stroup, T Scott
通讯作者：
Stroup, T Scott

Assessing metamotivation in schizophrenia: A pilot study of the Brief Regulation of Motivation Scale (BRoMS).

评估精神分裂症的元动机：动机简要调节量表（BRoMS）的初步研究。

DOI：
发表时间：
2022-11
期刊：
影响因子：
11.3
作者：
Lynch, David A;Brown, Marie;Saperstein, Alice;Stefancic, Ana;Medalia, Alice
通讯作者：
Medalia, Alice

Telehealth Acceptability and Feasibility Among People Served in a Community Behavioral Health System During the COVID-19 Pandemic.

COVID-19 大流行期间社区行为健康系统服务人员的远程医疗可接受性和可行性。

DOI：
发表时间：
2021-06
期刊：
影响因子：
0
作者：
Tse, Jeanie;LaStella, Drew;Chow, Elisa;Kingman, Emily;Pearlman, Shoshannah;Valeri, Linda;Wang, Hao;Dixon, Lisa B
通讯作者：
Dixon, Lisa B